PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Veeda Clinical Research Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Veeda Oncology Acquires Paris-based Biologie & Industrie - Veeda Oncology, the subsidiary of one of the leading Global CRO’s in India, Veeda Clinical Research Ltd, has completed the acquisition of Biologie et Industrie (B & I), an Oncology CRO founded in 1984, based in Paris, France
Veeda Oncology Acquires Paris-based Biologie & Industrie

 

NewswireToday - /newswire/ - Ahmedabad, Gujarat, India, 2008/05/22 - Veeda Oncology, the subsidiary of one of the leading Global CRO’s in India, Veeda Clinical Research Ltd, has completed the acquisition of Biologie et Industrie (B & I), an Oncology CRO founded in 1984, based in Paris, France.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Strengthens its global position in Oncology. Announced on Tuesday, 6th May 2008, Veeda Oncology, the subsidiary of one of the leading Global CRO’s in India, Veeda Clinical Research, has completed the acquisition of Biologie et Industrie (B & I), an Oncology CRO founded in 1984, based in Paris, France. The acquisition of B & I, with over 20 years of oncology CRO experience, significantly compliments Veeda Oncology’s capability within mainland Europe.

Announcing the acquisition, Mr. Binoy Gardi, Co-Managing Director of the Veeda Group, said “the acquisition of B & I is one significant pillar that we are adding to our global oncology presence within the oncology CRO marketplace”. Mr. Gardi added that “the clients of B & I will now be able to enjoy the strong global oncology patient accrual ability that currently exists within Veeda Oncology as well as the other full service capabilities that Veeda Oncology provides to their clients”.

Veeda Oncology is a global Oncology CRO with operations in India, Eastern Europe, Western Europe and the US. The company is a full service oncology CRO for Phase I through Phase IV studies with the unique capability of providing rapid and strong global patient accrual with an effective cost structure. Veeda Oncology feels that the acquisition of B & I truly strengthens Veeda Oncology’s capabilities.

Dr. Rémy Brossel, MD and Dr. (Mrs.) Sylvie Brossel, MD, will both remain with the company to lead the operations within Europe. Dr. Rémy Brossel is tremendously excited with the blending of B & I with Veeda Oncology since it will allow B & I to “participate in the global environment for oncology clinical trials for our clients and to add greatly to the capacity that we can provide our clients. Now, we can effectively provide access to patients in the US, Eastern Europe, India as well as central Europe.”

Mr. Matt Bowman, President and CEO of Veeda Oncology (veedacr.com), said “the addition of both Drs. Rémy and Sylvie Brossel and their team from B & I will have a great impact on our European presence. Combining this with our organization in Gorlitz, Germany allows for significant growth potential within the European market. In addition, all of our global clients will benefit from the 20 years of oncology expertise that B & I will bring to Veeda.”

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Veeda Clinical Research Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Veeda Oncology Acquires Paris-based Biologie & Industrie

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: VeedaCR.com 
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Veeda Clinical Research Ltd securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Veeda Clinical Research Ltd / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

ZOLL Canada Wins Tender to Equip Province of Québec Paramedic Services with ZOLL X Series Monitor/Defibrillators
Top Speakers, Brands Commit to SCBIO 2017 - SC Governor McMaster to Keynote Life Sciences Conference
Frost & Sullivan Recognizes Acelity as a Leader in the Field with its New V.A.C.ULTA™ 4 Therapy System and V.A.C. VERAFLO CLEANSE CHOICE™ Dressing
Frost & Sullivan Recognizes Ventec Life Systems for New Product Innovation - Game-changing, Modular Respiratory System, VOCSN
BD Expands Genomics Portfolio with New Single Cell Platform for RNA Expression Analysis
GE Healthcare Advances the Delivery of Cell Therapies with New Thawing Technology
Ansell Limited Announces the Closing of the Sale of its Sexual Wellness Business
PQ Bypass Earns Frost & Sullivan’s European Technology Innovation Award for its Proprietary DETOUR System for Percutaneous Bypass
Curaçao EMS Uses ZOLL Autopulse to Save Tourist in Sudden Cardiac Arrest
ZOLL to Showcase Expanded Portfolio of AEDs at Caravan Salon 2017
MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®
MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test
Datalogic Announces New Healthcare Memor X3 HC Mobile Computer
Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroAD™ Therapy System

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)